Barclays’s Aevi Genomic Medicine Inc GNMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-135
| Closed | – | – | 6721 |
|
|
2019
Q4 | $0 | Sell |
135
-17
| -11% | -$2 | ﹤0.01% | 7120 |
|
|
2019
Q3 | $0 | Buy |
152
+83
| +120% | +$15 | ﹤0.01% | 7394 |
|
|
2019
Q2 | $0 | Hold |
69
| – | – | ﹤0.01% | 7508 |
|
|
2019
Q1 | $0 | Hold |
69
| – | – | ﹤0.01% | 7529 |
|
|
2018
Q4 | $0 | Hold |
69
| – | – | ﹤0.01% | 7626 |
|
|
2018
Q3 | $0 | Hold |
69
| – | – | ﹤0.01% | 7589 |
|
|
2018
Q2 | $0 | Sell |
69
-1
| -1% | -$2 | ﹤0.01% | 7480 |
|
|
2018
Q1 | $0 | Sell |
70
-99
| -59% | -$186 | ﹤0.01% | 7507 |
|
|
2017
Q4 | $0 | Hold |
169
| – | – | ﹤0.01% | 7246 |
|
|
2017
Q3 | $0 | Sell |
169
-26,094
| -99% | -$33.3K | ﹤0.01% | 7175 |
|
|
2017
Q2 | $35K | Buy |
26,263
+25,953
| +8,372% | +$37.5K | ﹤0.01% | 5534 |
|
|
2017
Q1 | $0 | Buy |
310
+227
| +273% | +$1.03K | ﹤0.01% | 7106 |
|
|
2016
Q4 | $0 | Sell |
83
-88
| -51% | -$463 | ﹤0.01% | 6968 |
|
|
2016
Q3 | $1K | Buy |
+171
| New | +$975 | ﹤0.01% | 6513 |
|
|
2015
Q4 | – | Sell |
-88
| Closed | -$1K | – | 6869 |
|
|
2015
Q3 | $1K | Sell |
88
-234
| -73% | -$1.81K | ﹤0.01% | 6687 |
|
|
2015
Q2 | $2K | Buy |
+322
| New | +$2.5K | ﹤0.01% | 6858 |
|
|
2014
Q3 | – | Sell |
-700
| Closed | -$5K | – | 7915 |
|
|
2014
Q2 | $5K | Buy |
+700
| New | +$4.95K | ﹤0.01% | 7145 |
|
Barclays's GNMX Position: Q1 2020 in Review
Barclays sold out of Aevi Genomic Medicine Inc (GNMX) in Q1 2020, closing a stake of 135 shares.
Barclays first reported a position in GNMX in Q2 2014 and held it in 17 quarters. The position peaked at $35K in Q2 2017. 2 funds tracked by Wall St. Rank hold GNMX as of Q1 2020.
- Barclays reported no remaining Aevi Genomic Medicine Inc position as of Q1 2020 after selling out during the quarter.
- Barclays sold 135 Aevi Genomic Medicine Inc shares in Q1 2020.
- Barclays first reported a position in Aevi Genomic Medicine Inc in Q2 2014 and held it in 17 quarters.
- Barclays's Aevi Genomic Medicine Inc position peaked at $35K in Q2 2017.
- 2 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q1 2020.
Based on Barclays's 13F filing for Q1 2020, filed 13 May 2020.